07:00 , Oct 10, 2016 |  BC Extra  |  Company News

Nicox's eye drop gets complete response letter

Nicox S.A. (Euronext:COX) received a complete response letter from FDA for AC-170 to treat ocular itching associated with allergic conjunctivitis. The company said the letter related "solely" to a GMP inspection at a third party...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Clinical News

Cetirizine regulatory update

FDA accepted and granted Priority Review to an NDA from Nicox for AC-170 to treat ocular itching associated with allergic conjunctivitis. The PDUFA date is Oct. 18. The product is a topical formulation of cetirizine,...
08:00 , Nov 10, 2014 |  BC Week In Review  |  Company News

Aciex Therapeutics, Nicox deal

Nicox completed its acquisition of Aciex (see BioCentury, July 14). Aciex Therapeutics Inc. , Boston, Mass.   Nicox S.A. (Euronext:COX), Sophia Antipolis, France   Business: Ophthalmic  ...
07:00 , Jul 14, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) was down $0.96 to $10.54 last week after partner Gruenenthal Group submitted an MAA to EMA for Zalviso to treat moderate to severe acute pain. The submission triggered a...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Company News

Nicox S.A, Aciex Therapeutics deal

Nicox will acquire ophthalmic play Aciex in a stock deal worth up to $120 million. Aciex shareholders will receive an upfront payment of $65 million through the issue of 20.6 million Nicox shares, plus contingent...
00:43 , Jul 3, 2014 |  BC Extra  |  Company News

Nicox to acquire Aciex

Nicox S.A. (Euronext:COX) announced it will acquire ophthalmic play Aciex Therapeutics Inc. (Westborough, Mass.) in a stock deal worth up to $120 million. Aciex shareholders will receive an upfront stock payment of $65 million and...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Clinical News

PRT062070: Phase I/II started

Portola began an open-label Phase I/II trial of PRT2070. The Phase I portion will evaluate escalating doses of PTR2070 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma...
08:00 , Mar 4, 2013 |  BC Week In Review  |  Company News

Aciex Therapeutics, Portola deal

Portola granted Aciex exclusive rights to co-develop Portola's portfolio of small molecule dual spleen tyrosine kinase (SYK) and Janus kinase (JAK) inhibitors for ophthalmic indications. The portfolio includes preclinical and early stage undisclosed compounds, including...
02:08 , Feb 28, 2013 |  BC Extra  |  Company News

Portola, Aciex in ophthalmic deal

Portola Pharmaceuticals Inc. (South San Francisco, Calif.) granted Aciex Therapeutics Inc. (Westborough, Mass.) exclusive rights to co-develop Portola's portfolio of small molecule dual spleen tyrosine kinase (SYK) and Janus kinase (JAK) inhibitors for ophthalmic indications....
07:00 , Aug 8, 2011 |  BC Week In Review  |  Company News

Aciex Therapeutics, Akorn deal

Akorn acquired an undisclosed minority stake in ophthalmic company Aciex and also received worldwide rights to an undisclosed OTC eye care product from Aciex. Akorn also signed a manufacturing deal for an undisclosed prescription product...